Outlook Therapeutics Inc. (NASDAQ: OTLK)
$9.23
+0.7800 ( +9.23% ) 262.8K
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.